top of page

Conclusions & Recommendations

20.12.1 - Niger

Conclusion/Recommendation:

TEC congratulated Niger MOH and ITI for their collaboration in improving supply chain management in-country, and for the efforts toward cross-border collaboration with Nigeria to prevent unauthorized movement of NTD drugs.

Action:

This message was conveyed to the Niger MOH.

TEC 20

2019

Africa - West

Niger

supply chain, cross-border

20.12.2 - Niger

Conclusion/Recommendation:

TEC noted with concern the challenges in the Niger trachoma program over the years that may have compromised progress towards elimination. These include low reported coverage and skipped and/or delayed MDAs. As a result, TEC is concerned about the use of donated Zithromax®, which could put future donations at risk.

Action:

ITI sent a letter to the Niger MOH to share this recommendation.

TEC 20

2019

Africa - West

Niger

coverage, Zithromax® donation criteria

20.12.3 - Niger

Conclusion/Recommendation:

TEC recommends a multi-pronged approach to address challenges in the Niger program:
- An independent external NTD program assessment (funded by ITI) to fully understand the factors at all levels resulting in delayed MDAs and poor coverage;
- High-level meetings and advocacy by partners, including USAID, DFID, and ITI as donors, to review the challenges and identify opportunities for improved planning, coordination, and implementation.

Action:

Niger was very enthusiastic about this approach. Timing has been an issue, but an independent assessment is now planned and scheduled for December 2019.
As of TEC 22, the Niger program assessment was completed in Q1 2020; findings and recommendations from the assessment will be presented at TEC 22.

TEC 20

2019

Africa - West

Niger

coverage, recommendations for ITI management

20.2.1 - ITI Supply Chain Team

Conclusion/Recommendation:

TEC congratulates the ITI Supply Chain team for their work in building supply chain capacity in donation countries. Their presentations on the supply chain strengthening plan, and actions undertaken and follow up in some countries were extremely clear and informative. They are requested to share their plans and collaborate with partners who have similar activities in their budgets.

Action:

This is noted and is being achieved through the NTD Supply Chain Forum.

TEC 20

2019

supply chain

20.2.2 - ITI Supply Chain Team

Conclusion/Recommendation:

TEC recommends that the ITI Supply Chain team finalize and share their SOPs and other supply chain tools with other NTD programs.

Action:

This is being achieved through the NTD Supply Chain Forum.

TEC 20

2019

supply chain

20.2.3 - ITI Supply Chain Team

Conclusion/Recommendation:

TEC recommends to ITI management to invite supply chain and management representatives from the other NTD pharmaceutical donors to future Summer TEC meetings.

Action:

ITI Management will continue to invite representatives from the other pharmaceutical companies, and would welcome TEC members’ suggestions of specific key invitees. Previous invitees have been unable to attend. TEC 22’s online format facilitated participation from a broader range of interested parties.

TEC 20

2019

supply chain, recommendations for ITI management, TEC meeting management

20.3.1 - WHO participation as Observers at TEC

Conclusion/Recommendation:

TEC acknowledged the presence of the World Health Organization representatives from Headquarters, PAHO, and ESPEN/AFRO and recommend that an open invitation be extended to them (and other WHO Regional Offices, as appropriate) as Observers at future TEC meetings.

Action:

This is noted and ITI Management will continue to invite WHO representatives from the regional offices, as determined by agenda topics and meeting location.

TEC 20

2019

TEC meeting management

20.4.1 - Engagement with DFID and Crown Agents for Ascend Funding

Conclusion/Recommendation:

TEC notes that for 2020, 14.5 million treatments in 86 districts were approved contingent on confirmation of funding where the presumed funding source is DFID/Ascend-Crown Agents, and where implementing partners are not yet identified. Given that Crown Agents is a new entity in the implementation of NTD programs, TEC recommends that ITI work closely with DFID-Ascend and Crown Agents to identify funding needs, support the inception phase, and identify where future assistance may be required.

Action:

ITI Management have been in contact with Crown Agents to provide the 2019 and 2020 funding gaps list, in areas previously supported by DFID funding. A Crown Agents representative was again invited to participate in the TEC 21 meeting; unfortunately, they were unable to send anyone. ITI Management will continue to engage with them. ITI continued to welcome engagement with Crown Agents, and Crown were invited as Observers at TEC 22.

TEC 20

2019

funding, recommendations for ITI management

20.5.1 - Ethiopia

Conclusion/Recommendation:

TEC recommends to ITI to include a clause in the MOU with Ethiopia to require Zithromax® inventory reporting prior to each shipment, upon request.

Action:

A clause was included in the 2020 MOU.

TEC 20

2019

Africa - East

Ethiopia

supply chain, recommendations for ITI management

20.6.1 - Ethiopia: Gambella

Conclusion/Recommendation:

Due to high population movement, TEC recommends that ITI request that the Ethiopian FMOH and Gambella RHB provide new population figures for each refugee camp.

Action:

This will be done for the 2021 Zithromax® Application. For TEC 22, the population of refugee camps was updated through Ethiopia’s Administration for Refugee and Returnee Affairs (ARRA) and reflected in the 2021 Zithromax® Application.

TEC 20

2019

Africa - East

Ethiopia

special populations, Zithromax® donation criteria

International Trachoma Initiative

330 West Ponce de Leon Avenue

Decatur, GA 30030 

Phone:

+1 800 765 7173
+1 404 371 0466
Fax:

+1 404 371 1087

  • Instagram
  • Facebook
  • Twitter
  • YouTube
bottom of page